AFF1 and acute lymphoblastic leukemia: In the Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP) and Berlin-Frankfurt-Münster (BFM) ALL 2000 protocol, patients 1 to 17 years old with standard-risk B-ALL, defined by the absence of high-risk genetic features (BCR-ABL1, KMT2A-AFF1) and the lack MRD disease (i.e., level < 1 × 10–4) on days 33 and 78 from the start of remission induction treatment, were randomized to receive standard or reduced delayed intensification treatment [17].